Alethio Therapeutics
PrivateLast Round
Series A
Nov 5, 2026
Total Funding Raised
$97.96M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Alethio Therapeutics operates in Healthcare & Life Sciences and is based in Abingdon. Its latest recorded funding round was a Series A round in November 2026.
Alethio Therapeutics is a biotechnology company that develops disease-modifying therapies for patients with chronic blood cancers, specifically myeloproliferative neoplasms (MPNs).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alethio Therapeutics Comparables
Compare Alethio Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Johnson & Johnson | 77% | |
| Step Pharma | 76% | |
| Atavistik Bio | 76% |
For institutional investors. Book with your work email.
Alethio Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 5, 2026 | ||||
| Seed | Dec 15, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Alethio Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| Oxford Science Enterprises | Seed, Series A |
| University of Oxford | Series A |
| Sofinnova Partners | Series A |
| Cancer Research Horizons | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2026
Developing a program for mutant calreticulin-driven disease, found in 30% of MPN patients.
- Nov 6, 2026
ARTEMIS identifies and validates new drug targets in myeloproliferative neoplasms.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 9, 2026
Alethio Therapeutics, Inc., launched as Alethiomics in 2021, aims to develop targeted therapies for this family of blood cancers affecting the bone marrow.
- is_developingNov 6, 2026
Alethio Therapeutics, Inc. is developing a programme for mutant calreticulin-driven disease, found in roughly 30% of patients with MPNs.
- is_developingNov 5, 2026
Alethio Therapeutics, Inc. is developing targeted therapies designed to selectively eliminate the disease-driving cells that sustain MPNs, with the goal of modifying underlying disease features, restoring healthy blood counts, reducing thrombotic risk, and improving patient outcomes; its ATX-011 program advances through IND-enabling studies toward clinical development in ET.
- attends_eventNov 5, 2026
Alethio Therapeutics, Inc. has preclinical data for ATX-011 selected for oral presentation at the ASH 2026 Annual Meeting, highlighting its first-in-class G6B-targeting programme.
- is_developingNov 5, 2026
In Nov '26, Alethio Therapeutics, Inc. plans to develop a new generation of therapies for myeloproliferative neoplasms (MPNs), led by preclinical ATX-011, with Series A funding supporting its transition to a clinical-stage company.
For institutional investors. Book with your work email.
Alethio Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alethio Therapeutics's valuation, stock price, and market status.
Is Alethio Therapeutics a public or private company?
Alethio Therapeutics is a private company.
What is the current stock price of Alethio Therapeutics?
Alethio Therapeutics is a private company, so its shares have no public market price. Caplight tracks Alethio Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alethio Therapeutics worth (valuation)?
Valuation information for Alethio Therapeutics is not publicly available.
Can I buy Alethio Therapeutics stock?
Alethio Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alethio Therapeutics's last funding round?
Alethio Therapeutics's most recent funding round was Series A on November 5, 2026.
Who are the main investors in Alethio Therapeutics?
Key investors in Alethio Therapeutics include RA Capital Management, Oxford Science Enterprises, Sofinnova Partners.
Will Alethio Therapeutics IPO soon?
No public IPO plans have been announced for Alethio Therapeutics.
How can I track Alethio Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Alethio Therapeutics's shares on secondary markets.